Category Archives: Public Policy

Latest From Public Policy

Myriad Supreme Court Decision: BIO’s Statement

4973532326_6c75ba32ba copy

Statement On U.S. Supreme Court Review Of Isolated DNA Patents Washington, D.C. (June 13, 2013) Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on  the U.S. Supreme Court’s decision regarding Myriad Genetics’ patent claims on isolated DNA molecules: “The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting.  cDNA is the commercially most important form of DNA used in biotechnology.  Today’s decision offers urgently-needed Read More >

Patently BIOtech  |  2 Comments  |  Email This Post
Tags: , , , ,

IP in Latin America: Growing Recognition of the Importance of IP to Innovation

Photo by Márcio Cabral de Moura

The Inter-American Dialogue’s daily Latin America Advisor recently asked the question “How seriously do Latin American countries protect IP rights?”  The editors asked various stakeholders about the U.S. Trade Representative’s Special 301 Report and its evaluation of Latin America’s protection of IP rights.  BIO’s Director for International Affairs, Meredith Fensom, commented on the growth of the innovative biotechnology sectors in Latin America and the critical role intellectual property plays.  “The presence of more than 60 Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Gene Patents, Angelina Jolie, and Reality

Gene Patents, Angelina Jolie, and Reality

By Dr. Hans Sauer, J.D., Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization  Angelina Jolie recently announced her personal connection with breast cancer and Myriad’s BRCA genetic test.  While Jolie’s post was a commendable personal account of the real world impact of breast cancer and the real world impact of developments in healthcare technology, a few less informed individuals have tried to take advantage of this recent announcement from stardom and spread misinformation.  Let’s Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , ,

Canada Patent Utility: Former USPTO Director Interview at BIO Convention

Photo credit to Meddy Garnet

David Kappos, former Director, US Patent and Trade Office and current Partner Cravath, Swaine and Moore, LLP discusses the Canadian Utility Requirement.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

What OxyContin Tells Us About the Value of “Evergreening” and Patents

Be.Futureproof

A few weeks ago, the  FDA announced that they would not allow generic versions of older versions of OxyContin. The original formulation of OxyContin goes off patent today. The original formulation did not have “tamper-resistant qualities” that prevent people from “crushing, breaking, and dissolution using a variety of tools and solvents.”  The article reports that the decision will keep Teva Pharmaceuticals and Impax Laboratories from making the older version which the FDA has determined is too dangerous Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,